MIRA Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance
MIRA Pharmaceuticals, Inc. (MIRA) had Deferred Tax Assets, Valuation Allowance of $9.59 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $9.59M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $6.93M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $3.61M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $1.78M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $9.59M 10-K · filed 2026-03-31 |
| 2024-12-31 | $6.93M 10-K · filed 2026-03-31 |
| 2023-12-31 | $3.61M 10-K · filed 2025-03-28 |
| 2022-12-31 | $1.78M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |